Invesco Pharmaceuticals ETF (PJP)
| Assets | $582.81M |
| Expense Ratio | 0.58% |
| PE Ratio | 28.31 |
| Forward PE | 12.98 |
| Shares Out | 4.61M |
| Dividend | $1.13 (0.87%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 24.86% |
| Volume | 20,616 |
| Open | 127.83 |
| Previous Close | 126.78 |
| Day's Range | 127.83 - 128.67 |
| 52-Week Low | 97.15 |
| 52-Week High | 132.59 |
| Beta | 0.43 |
| Holdings | 31 |
| Inception Date | Jun 23, 2005 |
About PJP
Fund Home PageThe Invesco Pharmaceuticals ETF (PJP) is an exchange-traded fund that mostly invests in health care stocks. The fund tracks an index of US pharmaceutical companies selected and weighted based on various factors using a quantitative methodology. PJP was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
52.55% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 6.14% |
| Eli Lilly and Company | LLY | 6.01% |
| AbbVie Inc. | ABBV | 6.00% |
| Amgen Inc. | AMGN | 5.69% |
| Pfizer Inc. | PFE | 5.63% |
| Johnson & Johnson | JNJ | 5.54% |
| Abbott Laboratories | ABT | 5.18% |
| Merck & Co., Inc. | MRK | 5.14% |
| Viatris Inc. | VTRS | 3.72% |
| Biogen Inc. | BIIB | 3.51% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 21, 2026 | $0.30136 | Sep 25, 2026 |
| Jun 22, 2026 | $0.27334 | Jun 26, 2026 |
| Mar 23, 2026 | $0.30902 | Mar 27, 2026 |
| Dec 22, 2025 | $0.24629 | Dec 26, 2025 |
| Sep 22, 2025 | $0.23633 | Sep 26, 2025 |
| Jun 23, 2025 | $0.26679 | Jun 27, 2025 |
Performance
PJP had a total return of 35.22% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.94%.
News
How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks
Many of the hot new drug candidates in the U.S. were developed Chinese companies.
Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excl...
Kospi jumps 6% as Asia's battered semiconductor trade rebounds
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a ba...
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Trump to announce discount drug pricing expansion, White House official says
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday, ...
Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Britain agrees full text of US-UK pharmaceutical trade deal
Britain said on Thursday it had agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.
Ozempic—and 14 other popular prescription drugs—will cost less for Medicare after the U.S. government negotiated lower prices
The price cuts will save Medicare billions of dollars in prescription-drug spending.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Best Pharmaceutical ETFs for Q4 2020
The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.